Enteritis of the ileal conduit as an adverse event related to immune checkpoint inhibitor use

Q4 Medicine

IJU Case Reports Pub Date : 2024-10-14 DOI:10.1002/iju5.12797

Ko Kobayashi, Kohei Hashimoto, Toshiaki Tanaka, Naoya Masumori

{"title":"Enteritis of the ileal conduit as an adverse event related to immune checkpoint inhibitor use","authors":"Ko Kobayashi, Kohei Hashimoto, Toshiaki Tanaka, Naoya Masumori","doi":"10.1002/iju5.12797","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Gastroenterocolitis is one of the adverse events related to immune checkpoint inhibitors. However, inflammation of the intestinal lesion used for urinary diversion is not well known as an adverse event related to their use.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>A patient with metastatic bladder cancer was administered pembrolizumab as second-line treatment. After 12 days of administration, he felt abdominal distention. Computed tomography demonstrated thickening of the ileal conduit wall and bilateral hydronephrosis. Biopsy of the ileal conduit revealed inflammatory granulation tissue. Biopsy of the sigmoid colon also revealed colitis. Therefore, we diagnosed enterocolitis including the ileal conduit related to pembrolizumab. We then started to administer 30 mg prednisolone. After this treatment, we confirmed improvement of the clinical symptoms and healing of the ileal conduit mucosa.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Inflammation of an ileal conduit can occur as an immune-related adverse event caused by metastatic urothelial carcinoma treatment with pembrolizumab.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"24-27"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693106/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12797","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Gastroenterocolitis is one of the adverse events related to immune checkpoint inhibitors. However, inflammation of the intestinal lesion used for urinary diversion is not well known as an adverse event related to their use.

Case presentation

A patient with metastatic bladder cancer was administered pembrolizumab as second-line treatment. After 12 days of administration, he felt abdominal distention. Computed tomography demonstrated thickening of the ileal conduit wall and bilateral hydronephrosis. Biopsy of the ileal conduit revealed inflammatory granulation tissue. Biopsy of the sigmoid colon also revealed colitis. Therefore, we diagnosed enterocolitis including the ileal conduit related to pembrolizumab. We then started to administer 30 mg prednisolone. After this treatment, we confirmed improvement of the clinical symptoms and healing of the ileal conduit mucosa.

Conclusion

Inflammation of an ileal conduit can occur as an immune-related adverse event caused by metastatic urothelial carcinoma treatment with pembrolizumab.

Abstract Image

查看原文本刊更多论文

回肠导管肠炎作为免疫检查点抑制剂使用相关的不良事件。

胃肠结肠炎是与免疫检查点抑制剂相关的不良事件之一。然而，用于尿转移的肠道病变炎症并不是众所周知的与它们的使用相关的不良事件。病例介绍：转移性膀胱癌患者给予派姆单抗作为二线治疗。服药12天后，他感到腹胀。计算机断层扫描显示回肠导管壁增厚和双侧肾积水。回肠导管活检显示炎性肉芽组织。乙状结肠活检也显示结肠炎。因此，我们诊断出与派姆单抗相关的肠结肠炎包括回肠导管。经此治疗后，我们证实临床症状改善，回肠导管粘膜愈合。结论：使用派姆单抗治疗转移性尿路上皮癌时，回肠导管炎症可作为免疫相关不良事件发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊